First-line combination therapy versus first-line monotherapy for primary hypertension

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Clinical guidelines suggest initiating hypertension treatment with either monotherapy or combination therapy.
• Evidence supporting these recommendations regarding clinically relevant outcomes is lacking.
• The comparative harm-to-benefit balance of initial antihypertensive strategies remains unknown.

Purpose of the Study:

• To compare clinical outcomes between monotherapy and combination therapy as initial treatments for primary hypertension.

Main Methods:

• Systematic review and meta-analysis of randomized, double-blind trials with at least 12 months follow-up.
• Included trials compared initial combination antihypertensive therapy with monotherapy in adults with primary hypertension.
• Primary outcomes included mortality, cardiovascular events, and serious adverse events.

Main Results:

• Four trials with limited participants were included; data for initiating treatment subgroups were requested.
• Evidence for mortality, cardiovascular events, and serious adverse events was of very low certainty due to imprecision and subgroup analysis.
• Extremely wide confidence intervals indicate uncertainty regarding the harm-to-benefit balance of initial combination therapy versus monotherapy.

Conclusions:

• The number of participants and events in the included studies were too small to draw conclusions.
• Further large-scale clinical trials are necessary to compare the efficacy of initial monotherapy versus combination therapy for primary hypertension.
• Clinically relevant endpoints must be prioritized in future hypertension treatment research.